{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:08:06Z","timestamp":1788448086448,"version":"build-2803163510"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T00:00:00Z","timestamp":1518652800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10238-018-0491-8","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T13:52:58Z","timestamp":1518702778000},"page":"297-318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["The role of the alternative pathway of complement activation in glomerular diseases"],"prefix":"10.1007","volume":"18","author":[{"given":"Emilia","family":"\u0141ukawska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Polcyn-Adamczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia I.","family":"Niemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,15]]},"reference":[{"issue":"1","key":"491_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/cr.2009.139","volume":"20","author":"JR Dunkelberger","year":"2010","unstructured":"Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20(1):34\u201350.","journal-title":"Cell Res"},{"issue":"4","key":"491_CR2","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1074\/jbc.M114.605691","volume":"290","author":"E Rodriguez","year":"2015","unstructured":"Rodriguez E, Nan R, Li K, Gor J, Perkins SJ. A revised mechanism for the activation of complement C3 to C3b: a molecular explanation of a disease-associated polymorphism. J Biol Chem. 2015;290(4):2334\u201350.","journal-title":"J Biol Chem"},{"key":"491_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1034\/j.1600-065X.2001.1800103.x","volume":"180","author":"A Sahu","year":"2001","unstructured":"Sahu A, Lambris JD. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev. 2001;180:35\u201348.","journal-title":"Immunol Rev"},{"issue":"1","key":"491_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000163873","volume":"62","author":"L Singer","year":"1994","unstructured":"Singer L, Colten HR, Wetsel RA. Complement C3 deficiency: human, animal, and experimental models. Pathobiology. 1994;62(1):14\u201328.","journal-title":"Pathobiology"},{"issue":"3","key":"491_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/1721727X1201000308","volume":"10","author":"DM Valero-Herv\u00e1s","year":"2012","unstructured":"Valero-Herv\u00e1s DM, Morales P, Castro MJ, et al. Complement C3 genotyping of slow and fast variants by real time PCR-high resolution melting. Eur J Infamm. 2012;10(3):329\u201334.","journal-title":"Eur J Infamm"},{"issue":"1","key":"491_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/PAT.0000000000000042","volume":"46","author":"JR Delanghe","year":"2014","unstructured":"Delanghe JR, Speeckaert R, Speeckaert MM. Complement C3 and its polymorphism: biological and clinical consequences. Pathology. 2014;46(1):1\u201310.","journal-title":"Pathology"},{"issue":"5","key":"491_CR7","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1681\/ASN.2015060612","volume":"27","author":"S Sethi","year":"2016","unstructured":"Sethi S, Haas M, Markowitz GS, et al. Mayo clinic\/renal pathology society consensus report on pathologic classification, diagnosis, and reporting of GN. J Am Soc Nephrol. 2016;27(5):1278\u201387.","journal-title":"J Am Soc Nephrol"},{"key":"491_CR8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.5500\/wjt.v6.i4.632","volume":"6","author":"M Salvadori","year":"2016","unstructured":"Salvadori M, Bertoni E. Complement related kidney diseases: recurrence after transplantation. World J Transplant. 2016;6:632\u201345.","journal-title":"World J Transplant"},{"issue":"8","key":"491_CR9","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nrneph.2010.85","volume":"6","author":"F Fakhouri","year":"2010","unstructured":"Fakhouri F, Fr\u00e9meaux-Bacchi V, No\u00ebl LH, Cook HT, Pickering MC. C3 glomerulopathy: a new classification. Nat Rev Nephrol. 2010;6(8):494\u20139.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"491_CR10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ki.2013.377","volume":"84","author":"MC Pickering","year":"2013","unstructured":"Pickering MC, D\u2019Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013;84(6):1079\u201389.","journal-title":"Kidney Int"},{"key":"491_CR11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1073\/pnas.82.3.708","volume":"82","author":"MHL Bruijn De","year":"1985","unstructured":"De Bruijn MHL, Fey GH. Human complement component C3: cDNA coding sequence and derived primary structure. Proc Natl Acad Sci. 1985;82:708\u201312.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"491_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1365-3083.2006.01729.x","volume":"63","author":"ES Reis","year":"2006","unstructured":"Reis ES, Falc\u0103o DA, Isaac L. Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand J Immunol. 2006;63(3):155\u201368.","journal-title":"Scand J Immunol"},{"issue":"8","key":"491_CR13","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1074\/mcp.M115.056473","volume":"15","author":"ZA Chen","year":"2016","unstructured":"Chen ZA, Pellarin R, Fischer L, et al. Structure of complement C3(H2O) revealed by quantitative cross-linking\/mass spectrometry and modeling. Mol Cell Proteom. 2016;15(8):2730\u201343.","journal-title":"Mol Cell Proteom"},{"issue":"7116","key":"491_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nature05172","volume":"444","author":"BJ Janssen","year":"2006","unstructured":"Janssen BJ, Christodoilidou A, McCarthy A, Lambris JD, Gross P. Structure of C3b reveals conformational changes that underlie complement activity. Nature. 2006;444(7116):213\u20136.","journal-title":"Nature"},{"issue":"3","key":"491_CR15","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.4049\/jimmunol.176.3.1305","volume":"176","author":"JM Thurman","year":"2006","unstructured":"Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol. 2006;176(3):1305\u201310.","journal-title":"J Immunol"},{"issue":"7","key":"491_CR16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrneph.2016.70","volume":"12","author":"D Ricklin","year":"2016","unstructured":"Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 2016;12(7):383\u2013401.","journal-title":"Nat Rev Nephrol"},{"key":"491_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-immunol-030409-101250","volume":"28","author":"C Kemper","year":"2010","unstructured":"Kemper C, Atkinson JP, Hourcade DE. Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol. 2010;28:131\u201355.","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"491_CR18","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.15252\/embj.201696173","volume":"36","author":"DV Pedersen","year":"2017","unstructured":"Pedersen DV, Roumenina L, Jensen RK, et al. Functional and structural insight into properdin control of complement alternative pathway amplification. EMBO J. 2017;36(8):1084\u201399.","journal-title":"EMBO J"},{"issue":"7","key":"491_CR19","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/ni.1756","volume":"10","author":"SH Rooijakkers","year":"2009","unstructured":"Rooijakkers SH, Wu J, Ruyken M, et al. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol. 2009;10(7):721\u20137.","journal-title":"Nat Immunol"},{"issue":"1","key":"491_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00441-010-1034-0","volume":"343","author":"JV Sarma","year":"2011","unstructured":"Sarma JV, Ward PA. The complement system. Cell Tissue Res. 2011;343(1):227\u201335.","journal-title":"Cell Tissue Res"},{"key":"491_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0065-2776(08)04004-2","volume":"104","author":"PJ Lachmann","year":"2009","unstructured":"Lachmann PJ. The amplification loop of the complement pathways. Adv Immunol. 2009;104:115\u201349.","journal-title":"Adv Immunol"},{"issue":"163","key":"491_CR22","first-page":"79","volume":"28","author":"A Rochowiak","year":"2010","unstructured":"Rochowiak A, Niemir ZI. The structure and role of CR1 complement receptor in physiology. Pol Merkur Lekarski. 2010;28(163):79\u201383.","journal-title":"Pol Merkur Lekarski"},{"key":"491_CR23","first-page":"262","volume":"6","author":"NS Merle","year":"2015","unstructured":"Merle NS, Church SEL, Fremeaux-Bacchi V, Roumenina LT. Complement system part I: molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.","journal-title":"Front Immunol"},{"issue":"9","key":"491_CR24","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.2215\/CJN.06230614","volume":"10","author":"DR Mathern","year":"2015","unstructured":"Mathern DR, Heeger PS. Molecules great and small: the complement system. Clin J Am Soc Nephrol. 2015;10(9):1636\u201350.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"491_CR25","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.2215\/CJN.01710216","volume":"11","author":"JM Thurman","year":"2016","unstructured":"Thurman JM, Nester CM. All things complement. Clin J Am Soc Nephrol. 2016;11(10):1856\u201366.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"491_CR26","first-page":"257","volume":"26","author":"NS Merle","year":"2015","unstructured":"Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system part II: role in immunity. Front Immunol. 2015;26(6):257.","journal-title":"Front Immunol"},{"issue":"1","key":"491_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jcla.10100","volume":"18","author":"RF Ritchie","year":"2004","unstructured":"Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for complement proteins C3 and C4: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal. 2004;18(1):1\u20138.","journal-title":"J Clin Lab Anal"},{"issue":"6012","key":"491_CR28","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1126\/science.1195821","volume":"330","author":"F Forneris","year":"2010","unstructured":"Forneris F, Ricklin D, Wu J, et al. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science. 2010;330(6012):1816\u201320.","journal-title":"Science"},{"issue":"10","key":"491_CR29","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.15252\/embj.201593673","volume":"35","author":"F Forneris","year":"2016","unstructured":"Forneris F, Wu J, Xue X, et al. Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode. EMBO J. 2016;35(10):1133\u201349.","journal-title":"EMBO J"},{"issue":"8","key":"491_CR30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nsmb.3427","volume":"24","author":"X Xue","year":"2017","unstructured":"Xue X, Wu J, Ricklin D, et al. Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses. Nat Struct Mol Biol. 2017;24(8):643\u201351.","journal-title":"Nat Struct Mol Biol"},{"issue":"5","key":"491_CR31","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1681\/ASN.2005010078","volume":"16","author":"GB Appel","year":"2005","unstructured":"Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol. 2005;16(5):1392\u2013403.","journal-title":"J Am Soc Nephrol"},{"key":"491_CR32","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1681\/ASN.2014101000","volume":"26","author":"N Maillard","year":"2015","unstructured":"Maillard N, Wyatt RJ, Julian BA, et al. Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol. 2015;26:1503\u201312.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"491_CR33","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/ni.1755","volume":"10","author":"J Wu","year":"2009","unstructured":"Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, Gros P. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol. 2009;10(7):728\u201333.","journal-title":"Nat Immunol"},{"issue":"7","key":"491_CR34","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/jmg.2005.038315","volume":"43","author":"MA Abrera-Abeleda","year":"2006","unstructured":"Abrera-Abeleda MA, Nishimura C, Smith JL, et al. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet. 2006;43(7):582\u20139.","journal-title":"J Med Genet"},{"issue":"10","key":"491_CR35","doi-asserted-by":"publisher","first-page":"6250","DOI":"10.4049\/jimmunol.174.10.6250","volume":"174","author":"JL McRae","year":"2005","unstructured":"McRae JL, Duthy TG, Griggs KM, et al. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein. J Immunol. 2005;174(10):6250\u20136.","journal-title":"J Immunol"},{"issue":"10","key":"491_CR36","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.4049\/jimmunol.1403121","volume":"194","author":"\u00c1I Csincsi","year":"2015","unstructured":"Csincsi \u00c1I, Kopp A, Z\u00f6ldi M, et al. Factor H-related protein 5 interacts with pentraxin 3 and the extracellular matrix and modulates complement activation. J Immunol. 2015;194(10):4963\u201373.","journal-title":"J Immunol"},{"issue":"1","key":"491_CR37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/imr.12477","volume":"274","author":"N Medjeral-Thomas","year":"2016","unstructured":"Medjeral-Thomas N, Pickering MC. The complement factor H-related proteins. Immunol Rev. 2016;274(1):191\u2013201.","journal-title":"Immunol Rev"},{"issue":"12","key":"491_CR38","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1073\/pnas.1219260110","volume":"110","author":"E Goicoechea de Jorge","year":"2013","unstructured":"Goicoechea de Jorge E, Caesar JJ, Malik TH, et al. Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc Natl Acad Sci USA. 2013;110(12):4685\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"491_CR39","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1172\/JCI68280","volume":"123","author":"A Tortajada","year":"2013","unstructured":"Tortajada A, Y\u00e9benes H, Abarrategui-Garrido C, et al. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest. 2013;123(6):2434\u201346.","journal-title":"J Clin Invest"},{"issue":"1","key":"491_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1172\/JCI71866","volume":"124","author":"Q Chen","year":"2014","unstructured":"Chen Q, Wiesener M, Eberhardt HU, et al. Complement factor H-related hybrid protein deregulates complement in dense deposit disease. J Clin Invest. 2014;124(1):145\u201355.","journal-title":"J Clin Invest"},{"issue":"23","key":"491_CR41","doi-asserted-by":"publisher","first-page":"19528","DOI":"10.1074\/jbc.M112.364471","volume":"287","author":"M Hebecker","year":"2012","unstructured":"Hebecker M, J\u00f3zsi M. Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein. J Biol Chem. 2012;287(23):19528\u201336.","journal-title":"J Biol Chem"},{"key":"491_CR42","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3389\/fimmu.2017.01328","volume":"8","author":"AE Beek van","year":"2017","unstructured":"van Beek AE, Pouw RB, Brouwer MC, et al. Factor H-related (FHR)-1 and FHR-2 form homo- and heterodimers, while FHR-5 circulates only as homodimer in human plasma. Front Immunol. 2017;8:1328.","journal-title":"Front Immunol"},{"key":"491_CR43","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/2141042a0","volume":"214","author":"RJ Wieme","year":"1967","unstructured":"Wieme RJ, Demeulenaere L. Genetically determined electrophoretic variant of the human complement component C\u20193. Nature. 1967;214:1042\u20133.","journal-title":"Nature"},{"key":"491_CR44","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1172\/JCI105904","volume":"47","author":"CA Alper","year":"1968","unstructured":"Alper CA, Propp RP. Genetic polymorphism of the third component of human complement (C\u20193). J Clin Invest. 1968;47:2181\u201391.","journal-title":"J Clin Invest"},{"key":"491_CR45","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1084\/jem.172.4.1011","volume":"172","author":"M Botto","year":"1990","unstructured":"Botto M, Fong KY, So AK, Koch C, Walport MJ. Molecular basis of polymorphisms of human complement component C3. J Exp Med. 1990;172:1011\u20137.","journal-title":"J Exp Med"},{"issue":"3","key":"491_CR46","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1073\/pnas.0810860106","volume":"106","author":"E Torreira","year":"2009","unstructured":"Torreira E, Tortajada A, Montes T, Rodr\u00edguez de C\u00f3rdoba S, Llorca O. 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase. Proc Natl Acad Sci USA. 2009;106(3):882\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"491_CR47","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1056\/NEJMoa072618","volume":"357","author":"JR Yates","year":"2007","unstructured":"Yates JR, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357(6):553\u201361.","journal-title":"N Engl J Med"},{"issue":"9","key":"491_CR48","doi-asserted-by":"publisher","first-page":"8919","DOI":"10.1007\/s11033-012-1759-9","volume":"39","author":"N Bazyar","year":"2012","unstructured":"Bazyar N, Azarpira N, Khatami RS, Galehdari H. The investigation of allele and genotype frequencies of human C3 (rs2230199). Mol Biol Rep. 2012;39(9):8919\u201324.","journal-title":"Mol Biol Rep"},{"key":"491_CR49","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/BF00398796","volume":"23","author":"C Koch","year":"1986","unstructured":"Koch C, Behrendt N. A novel polymorphism of human complement component C3 detected by means of a monoclonal antibody. Immunogenetics. 1986;23:322\u20135.","journal-title":"Immunogenetics"},{"issue":"8","key":"491_CR50","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1681\/ASN.2010080795","volume":"22","author":"MA Abrera-Abeleda","year":"2011","unstructured":"Abrera-Abeleda MA, Nishimura C, Frees K, et al. Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol. 2011;22(8):1551\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"491_CR51","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1365-2249.1993.tb05917.x","volume":"91","author":"JE Finn","year":"1993","unstructured":"Finn JE, Mathieson PW. Molecular analysis of C3 allotypes in patients with nephritic factor. Clin Exp Immunol. 1993;91:410\u20134.","journal-title":"Clin Exp Immunol"},{"key":"491_CR52","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0022-3476(84)80110-9","volume":"105","author":"RH McLean","year":"1984","unstructured":"McLean RH, Winkelstein JA. Genetically determined variation in the complement system: relationship to disease. J Pediatr. 1984;105:179\u201388.","journal-title":"J Pediatr"},{"key":"491_CR53","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0272-6386(12)80376-3","volume":"23","author":"JE Finn","year":"1994","unstructured":"Finn JE, Li PK, Lai KN, Mathieson PW. Molecular analysis of C3 allotypes in Chinese patients with immunoglobulin A nephropathy. Am J Kidney Dis. 1994;23:543\u20136.","journal-title":"Am J Kidney Dis"},{"key":"491_CR54","first-page":"208","volume":"2","author":"M Rambausek","year":"1987","unstructured":"Rambausek M, van den Wall Bake AW, Schumacher-Ach R, et al. Genetic polymorphism of C3 and Bf in IgA nephropathy. Nephrol Dial Transplant. 1987;2:208\u201311.","journal-title":"Nephrol Dial Transplant"},{"key":"491_CR55","first-page":"1564","volume":"9","author":"JE Finn","year":"1994","unstructured":"Finn JE, Zhang L, Agrawal S, Jayne DR, Oliveira DB, Mathieson PW. Molecular analysis of C3 allotypes in patients with systemic vasculitis. Nephrol Dial Transplant. 1994;9:1564\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"491_CR56","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1159\/000355744","volume":"37","author":"U Persson","year":"2013","unstructured":"Persson U, Gullstrand B, Pettersson AG, Truedsson L, Segelmark MA. A candidate gene approach to ANCA-associated vasculitis reveals links to the C3 and CTLA-4 genes but not to the IL1-Ra and Fc\u0103-RIIa genes. Kidney Blood Press Res. 2013;37:641\u20138.","journal-title":"Kidney Blood Press Res"},{"key":"491_CR57","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa052825","volume":"354","author":"KM Brown","year":"2006","unstructured":"Brown KM, Kondeatis E, Vaughan RW, et al. Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med. 2006;354:2014\u201323.","journal-title":"N Engl J Med"},{"issue":"1","key":"491_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/1098-1004(2001)17:1<79::AID-HUMU22>3.0.CO;2-5","volume":"17","author":"W Matsuyama","year":"2001","unstructured":"Matsuyama W, Nakagawa M, Takashima H, Muranaga F, Sano Y, Osame M. Identification of a novel mutation(Tyr1081Ter) in sisters with hereditary component C3 deficiency and SLE-like symptoms. Hum Mutat. 2001;17(1):79.","journal-title":"Hum Mutat"},{"issue":"2","key":"491_CR59","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/rheumatology\/kem321","volume":"47","author":"H Miyagawa","year":"2008","unstructured":"Miyagawa H, Yamai M, Sakaguchi D, et al. Association of polymorphisms in complement component C3 gene with susceptibility to systemic lupus erythematosus. Rheumatology (Oxford). 2008;47(2):158\u201364.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"491_CR60","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/gene.2009.23","volume":"10","author":"B Rhodes","year":"2009","unstructured":"Rhodes B, Hunnangkul S, Morris DL, Hsaio LC, Graham DS, Nitsch D. The heritability and genetics of complement C3 expression in UK SLE families. Genes Immun. 2009;10(5):525\u201330.","journal-title":"Genes Immun"},{"issue":"6","key":"491_CR61","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1681\/ASN.2015040348","volume":"27","author":"S Chauvet","year":"2016","unstructured":"Chauvet S, Roumenina LT, Bruneau S, et al. A familial C3GN secondary to defective C3 regulation by complement receptor 1 and complement factor H. J Am Soc Nephrol. 2016;27(6):1665\u201377.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"491_CR62","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ki.2012.63","volume":"82","author":"A Servais","year":"2012","unstructured":"Servais A, No\u00ebl LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82(4):454\u201364.","journal-title":"Kidney Int"},{"key":"491_CR63","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1093\/hmg\/ddp289","volume":"18","author":"A Tortajada","year":"2009","unstructured":"Tortajada A, Montes T, Mart\u00ednez-Barricarte R, Morgan BP, Harris CL, de C\u00f3rdoba SR. The disease protective complement factor H allotypic variant Ile62 shows increased binding for C3b and enhanced cofactor activity. Hum Mol Genet. 2009;18:3452\u201361.","journal-title":"Hum Mol Genet"},{"key":"491_CR64","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","volume":"71","author":"P Iatropoulos","year":"2016","unstructured":"Iatropoulos P, Noris M, Melea C, et al. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol. 2016;71:131\u201342.","journal-title":"Mol Immunol"},{"key":"491_CR65","first-page":"961203317702254","volume":"1","author":"M Tan","year":"2017","unstructured":"Tan M, Hao JB, Chu H, et al. Genetic variants in FH are associated with renal histopathologic subtypes of lupus nephritis: a large cohort study from China. Lupus. 2017;1:961203317702254.","journal-title":"Lupus"},{"issue":"13","key":"491_CR66","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1016\/j.molimm.2007.02.012","volume":"44","author":"C Skerka","year":"2007","unstructured":"Skerka C, Lauer N, Weinberger AA, et al. Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol. 2007;44(13):3398\u2013406.","journal-title":"Mol Immunol"},{"key":"491_CR67","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000348654","volume":"181","author":"A Servais","year":"2013","unstructured":"Servais A, No\u00ebl LH, Fr\u00e9meaux-Bacchi V, Lesavre P. C3 glomerulopathy. Contrib Nephrol. 2013;181:185\u201393.","journal-title":"Contrib Nephrol"},{"issue":"5","key":"491_CR68","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2215\/CJN.07110810","volume":"6","author":"S Sethi","year":"2011","unstructured":"Sethi S, Fervenza FC, Zhang Y, Nasr SH, Leung N, Vrana J. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol. 2011;6(5):1009\u201317.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"491_CR69","doi-asserted-by":"publisher","first-page":"e1002079","DOI":"10.1371\/journal.pgen.1002079","volume":"7","author":"J Zhao","year":"2011","unstructured":"Zhao J, Wu H, Khosravi M, et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet. 2011;7(5):e1002079.","journal-title":"PLoS Genet"},{"issue":"5","key":"491_CR70","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1681\/ASN.2014010096","volume":"26","author":"L Zhu","year":"2015","unstructured":"Zhu L, Zhai YL, Wang FM, et al. Variants in complement factor H and complement factor H-related protein genes, CFHR3 and CFHR1, affect complement activation in IgA nephropathy. J Am Soc Nephrol. 2015;26(5):1195\u2013204.","journal-title":"J Am Soc Nephrol"},{"key":"491_CR71","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/ng.787","volume":"43","author":"AG Gharavi","year":"2011","unstructured":"Gharavi AG, Kiryluk K, Choi M, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011;43:321\u20137.","journal-title":"Nat Genet"},{"issue":"11","key":"491_CR72","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ng.3118","volume":"46","author":"K Kiryluk","year":"2014","unstructured":"Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46(11):1187\u201396.","journal-title":"Nat Genet"},{"key":"491_CR73","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12882-015-0032-6","volume":"16","author":"P Nozal","year":"2015","unstructured":"Nozal P, Garrido S, Mart\u00ednez-Ara J, et al. Case report: lupus nephritis with autoantibodies to complement alternative pathway proteins and C3 gene mutation. BMC Nephrol. 2015;16:40.","journal-title":"BMC Nephrol"},{"issue":"1","key":"491_CR74","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.bbrc.2005.02.159","volume":"330","author":"H Tsukamoto","year":"2005","unstructured":"Tsukamoto H, Horiuchi T, Kokuba H, et al. Molecular analysis of a novel hereditary C3 deficiency with systemic lupus erythematosus. Biochem Biophys Res Commun. 2005;330(1):298\u2013304.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9743","key":"491_CR75","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/S0140-6736(10)60670-8","volume":"376","author":"DP Gale","year":"2010","unstructured":"Gale DP, de Jorge EG, Cook HT, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet. 2010;376(9743):794\u2013801.","journal-title":"Lancet"},{"issue":"7","key":"491_CR76","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1681\/ASN.2012020166","volume":"23","author":"TH Malik","year":"2012","unstructured":"Malik TH, Lavin PJ, Goicoechea de Jorge E, et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol. 2012;23(7):1155\u201360.","journal-title":"J Am Soc Nephrol"},{"key":"491_CR77","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.molimm.2016.07.007","volume":"77","author":"X Xiao","year":"2016","unstructured":"Xiao X, Ghosseinc C, Tortajada A, et al. Familial C3 glomerulonephritis caused by a novel CFHR5-CFHR2 fusion gene. Mol Immunol. 2016;77:89\u201396.","journal-title":"Mol Immunol"},{"issue":"4","key":"491_CR78","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.kint.2017.04.025","volume":"92","author":"SK Togarsimalemath","year":"2017","unstructured":"Togarsimalemath SK, Sethi SK, Duggal R, et al. A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. Kidney Int. 2017;92(4):876\u201387.","journal-title":"Kidney Int"},{"issue":"5","key":"491_CR79","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00467-016-3577-0","volume":"32","author":"K Alfakeeh","year":"2017","unstructured":"Alfakeeh K, Azar M, Alfadhel M, Abdullah AM, Aloudah N, Alsaad KO. Rare genetic variant in the CFB gene presenting as atypical hemolytic uremic syndrome and immune complex diffuse membranoproliferative glomerulonephritis, with crescents, successfully treated with eculizumab. Pediatr Nephrol. 2017;32(5):885\u201391.","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"491_CR80","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1681\/ASN.2013070796","volume":"25","author":"MC Marinozzi","year":"2014","unstructured":"Marinozzi MC, Vergoz L, Rybkine T, et al. Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? J Am Soc Nephrol. 2014;25(9):2053\u201365.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"491_CR81","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/CJN.04700513","volume":"9","author":"NR Medjeral-Thomas","year":"2014","unstructured":"Medjeral-Thomas NR, O\u2019Shaughnessy MM, O\u2019Regan JA, et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol. 2014;9(1):46\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"key":"491_CR82","doi-asserted-by":"publisher","first-page":"248","DOI":"10.12688\/f1000research.10364.1","volume":"6","author":"HT Cook","year":"2017","unstructured":"Cook HT. C3 glomerulopathy. F1000Research. 2017;6:248.","journal-title":"F1000Research"},{"issue":"1","key":"491_CR83","doi-asserted-by":"publisher","first-page":"232470961769074","DOI":"10.1177\/2324709617690746","volume":"5","author":"O Elfituri","year":"2017","unstructured":"Elfituri O, Aardsma N, Setty S, Behm F, Czech K. Atypical plasmacytic proliferation in a case of C3 glomerulopathy: pathophysiology demystified. J Investig Med High Impact Case Rep. 2017;5(1):2324709617690746. https:\/\/doi.org\/10.1177\/2324709617690746","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"4","key":"491_CR84","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10157-016-1358-5","volume":"21","author":"N Ito","year":"2017","unstructured":"Ito N, Ohashi R, Nagata M. C3 glomerulopathy and current dilemmas. Clin Exp Nephrol. 2017;21(4):541\u201351.","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"491_CR85","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","volume":"83","author":"A Misra","year":"2004","unstructured":"Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore). 2004;83(1):18\u201334.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"491_CR86","first-page":"608","volume":"118","author":"KL Rose","year":"2008","unstructured":"Rose KL, Paixao-Cavalcante D, Fish J, et al. Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest. 2008;118(2):608\u201318.","journal-title":"J Clin Invest"},{"issue":"4","key":"491_CR87","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1699-0463.1993.tb00112.x","volume":"101","author":"JH Jansen","year":"1993","unstructured":"Jansen JH. Porcine membranoproliferative glomerulonephritis with intramembranous dense deposits (porcine dense deposit disease). APMIS. 1993;101(4):281\u20139.","journal-title":"APMIS"},{"issue":"3","key":"491_CR88","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1172\/JCI117751","volume":"95","author":"K H\u00f8g\u00e5sen","year":"1995","unstructured":"H\u00f8g\u00e5sen K, Jansen JH, Mollnes TE, Hovdenes J, Harboe M. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest. 1995;95(3):1054\u201361.","journal-title":"J Clin Invest"},{"issue":"4","key":"491_CR89","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/ng912","volume":"31","author":"MC Pickering","year":"2002","unstructured":"Pickering MC, Cook HT, Warren J, et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet. 2002;31(4):424\u20138.","journal-title":"Nat Genet"},{"issue":"25","key":"491_CR90","doi-asserted-by":"publisher","first-page":"9649","DOI":"10.1073\/pnas.0601094103","volume":"103","author":"MC Pickering","year":"2006","unstructured":"Pickering MC, Warren J, Rose KL, et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. PNAS. 2006;103(25):9649\u201354.","journal-title":"PNAS"},{"issue":"1","key":"491_CR91","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1681\/ASN.2012060571","volume":"24","author":"MM Ruseva","year":"2013","unstructured":"Ruseva MM, Vernon KA, Lesher AM, et al. Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency. J Am Soc Nephrol. 2013;24(1):43\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"491_CR92","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1681\/ASN.2012060570","volume":"24","author":"AM Lesher","year":"2013","unstructured":"Lesher AM, Zhou L, Kimura Y, et al. Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis. J Am Soc Nephrol. 2013;24(1):53\u201365.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"491_CR93","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1053\/j.ajkd.2013.02.370","volume":"62","author":"L Zand","year":"2013","unstructured":"Zand L, Kattah A, Fervenza FC, et al. C3 Glomerulonephritis associated with monoclonal gammopathy. Am J Kidney Dis. 2013;62(3):506\u201314.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"491_CR94","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1053\/j.ajkd.2010.06.021","volume":"56","author":"S Sethi","year":"2010","unstructured":"Sethi S, Sukov WR, Zhang Y, et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis. 2010;56(5):977\u201382.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"491_CR95","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1681\/ASN.2016030343","volume":"28","author":"MCh Marinozzi","year":"2017","unstructured":"Marinozzi MCh, Roumenina LT, Chauvet S, et al. Anti-factor B and anti-C3b autoantibodies in C3 glomerulopathy and Ig-associated membranoproliferative GN. J Am Soc Nephrol. 2017;28(5):1603\u201313.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"491_CR96","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/ki.2012.250","volume":"82","author":"D Paix\u00e3o-Cavalcante","year":"2012","unstructured":"Paix\u00e3o-Cavalcante D, L\u00f3pez-Trascasa M, Skattum L, et al. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int. 2012;82(10):1084\u201392.","journal-title":"Kidney Int"},{"issue":"1","key":"491_CR97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.116.1.1","volume":"116","author":"MR Daha","year":"1976","unstructured":"Daha MR, Fearon DT, Austen KF. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol. 1976;116(1):1\u20137.","journal-title":"J Immunol"},{"issue":"5","key":"491_CR98","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","volume":"92","author":"MC Marinozzi","year":"2017","unstructured":"Marinozzi MC, Chauvet S, Le Quintrec M, et al. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Kidney Int. 2017;92(5):1232\u201341.","journal-title":"Kidney Int"},{"issue":"11","key":"491_CR99","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.4049\/jimmunol.1402770","volume":"194","author":"C Blanc","year":"2015","unstructured":"Blanc C, Togarsimalemath SK, Chauvet S, et al. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J Immunol. 2015;194(11):5129\u201338.","journal-title":"J Immunol"},{"issue":"10","key":"491_CR100","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1172\/JCI43343","volume":"120","author":"R Mart\u00ednez-Barricarte","year":"2010","unstructured":"Mart\u00ednez-Barricarte R, Heurich M, Valdes-Ca\u00f1edo F, Vazquez-Martul E, Torreira E, Montes T. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest. 2010;120(10):3702\u201312.","journal-title":"J Clin Invest"},{"issue":"24","key":"491_CR101","doi-asserted-by":"publisher","first-page":"e7144","DOI":"10.1097\/MD.0000000000007144","volume":"96","author":"P Chen","year":"2017","unstructured":"Chen P, Zhu L, Yu F, et al. Different types of glomerulonephritis associated with the dysregulation of the complement alternative pathway in 2 brothers: a case report. Medicine (Baltimore). 2017;96(24):e7144.","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"491_CR102","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/ki.2008.354","volume":"75","author":"S Habbig","year":"2009","unstructured":"Habbig S, Mihatsch MJ, Heinen S, et al. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int. 2009;75(11):1230\u20134.","journal-title":"Kidney Int"},{"issue":"2","key":"491_CR103","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","volume":"66","author":"M Noris","year":"2015","unstructured":"Noris M, Remuzzi G. Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015. Am J Kidney Dis. 2015;66(2):359\u201375.","journal-title":"Am J Kidney Dis"},{"issue":"15","key":"491_CR104","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1182\/blood-2014-10-609073","volume":"125","author":"EC Schramm","year":"2015","unstructured":"Schramm EC, Roumenina LT, Rybkine T, et al. Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood. 2015;125(15):2359\u201369.","journal-title":"Blood"},{"issue":"21","key":"491_CR105","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1182\/blood-2016-11-709865","volume":"129","author":"TS Jokiranta","year":"2017","unstructured":"Jokiranta TS. HUS and atypical HUS. Blood. 2017;129(21):2847\u201356.","journal-title":"Blood"},{"issue":"3","key":"491_CR106","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201ckidney disease: improving global outcomes\u201d (KDIGO) controversies conference. Kidney Int. 2017;91(3):539\u201351.","journal-title":"Kidney Int"},{"issue":"1","key":"491_CR107","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/imr.12479","volume":"274","author":"LT Roumenina","year":"2016","unstructured":"Roumenina LT, Rayes J, Frimat M, Fremeaux-Bacchi V. Endothelial cells: source, barrier, and target of defensive mediators. Immunol Rev. 2016;274(1):307\u201329.","journal-title":"Immunol Rev"},{"issue":"12","key":"491_CR108","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2010030315","volume":"21","author":"MA Dragon-Durey","year":"2010","unstructured":"Dragon-Durey MA, Sethi SK, Bagga A, et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol. 2010;21(12):2180\u20137.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"491_CR109","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1182\/blood-2007-09-109876","volume":"111","author":"M J\u00f3zsi","year":"2008","unstructured":"J\u00f3zsi M, Licht C, Strobel S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1\/CFHR3 deficiency. Blood. 2008;111(3):1512\u20134.","journal-title":"Blood"},{"issue":"1","key":"491_CR110","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1053\/ajkd.2002.29873","volume":"39","author":"B Murphy","year":"2002","unstructured":"Murphy B, Georgiou T, Machet D, Hill P, McRae J. Factor H\u2013related protein-5: a novel component of human glomerular immune deposits. Am J Kidney Dis. 2002;39(1):24\u20137.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"491_CR111","doi-asserted-by":"publisher","first-page":"308","DOI":"10.5527\/wjn.v5.i4.308","volume":"5","author":"M Salvadori","year":"2016","unstructured":"Salvadori M, Rosso G. Reclassification of membranoproliferative glomerulonephritis: identification of a new GN: C3GN. World J Nephrol. 2016;5(4):308\u201320.","journal-title":"World J Nephrol"},{"issue":"9","key":"491_CR112","doi-asserted-by":"crossref","first-page":"287","DOI":"10.20452\/pamw.1077","volume":"121","author":"K Smyka\u0142-Jankowiak","year":"2011","unstructured":"Smyka\u0142-Jankowiak K, Niemir ZI, Polcyn-Adamczak M. Do circulating antibodies against C1q reflect the activity of lupus nephritis? Pol Arch Med Wewn. 2011;121(9):287\u201395.","journal-title":"Pol Arch Med Wewn"},{"issue":"1","key":"491_CR113","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000153344","volume":"33","author":"Z Tongmao","year":"1983","unstructured":"Tongmao Z. Genetic polymorphisms of C3 and Bf in the Chinese population. Hum Hered. 1983;33(1):36\u20138.","journal-title":"Hum Hered"},{"key":"491_CR114","doi-asserted-by":"publisher","first-page":"673","DOI":"10.12659\/MSM.903102","volume":"23","author":"X Yang","year":"2017","unstructured":"Yang X, Wei RB, Wang Y, et al. Decreased serum C3 levels in immunoglobulin A (IgA) nephropathy with chronic kidney disease: a propensity score matching study. Med Sci Monit. 2017;23:673\u201381.","journal-title":"Med Sci Monit"},{"issue":"2","key":"491_CR115","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1681\/ASN.2017010019","volume":"29","author":"P Jullien","year":"2018","unstructured":"Jullien P, Laurent B, Claisse G, et al. Deletion variants of CFHR1 and CFHR3 associate with mesangial immune deposits but not with progression of IgA nephropathy. J Am Soc Nephrol. 2018;29(2):661\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"491_CR116","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.kint.2017.03.043","volume":"92","author":"NR Medjeral-Thomas","year":"2017","unstructured":"Medjeral-Thomas NR, Lomax-Browne HJ, Beckwith H, et al. Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy. Kidney Int. 2017;92(4):942\u201352.","journal-title":"Kidney Int"},{"issue":"4","key":"491_CR117","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.kint.2017.03.041","volume":"92","author":"A Tortajada","year":"2017","unstructured":"Tortajada A, Guti\u00e9rrez E, Goicoechea de Jorge E, et al. Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy. Kidney Int. 2017;92(4):953\u201363.","journal-title":"Kidney Int"},{"issue":"164","key":"491_CR118","first-page":"144","volume":"28","author":"ZI Niemir","year":"2010","unstructured":"Niemir ZI, W\u0105growska-Danilewicz M. Renal involvement in systemic lupus erythematosus. Pol Merkur Lekarski. 2010;28(164):144\u201351.","journal-title":"Pol Merkur Lekarski"},{"issue":"5","key":"491_CR119","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2215\/CJN.05780616","volume":"12","author":"S Almaani","year":"2017","unstructured":"Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825\u201335.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"491_CR120","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10067-016-3491-7","volume":"36","author":"H Wakiguchi","year":"2017","unstructured":"Wakiguchi H, Takei S, Kubota T, Miyazono A, Kawano Y. Treatable renal disease in children with silent lupus nephritis detected by baseline biopsy: association with serum C3 levels. Clin Rheumatol. 2017;36(2):433\u20137.","journal-title":"Clin Rheumatol"},{"key":"491_CR121","first-page":"134","volume":"63","author":"K Smyka\u0142-Jankowiak","year":"2009","unstructured":"Smyka\u0142-Jankowiak K, Niemir ZI. Structure and function of complement protein C1q and its role in the development of autoimmune diseases. Postepy Hig Med Dosw (Online). 2009;63:134\u201341.","journal-title":"Postepy Hig Med Dosw (Online)"},{"issue":"1","key":"491_CR122","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/0961203314547791","volume":"24","author":"AM Orbai","year":"2015","unstructured":"Orbai AM, Truedsson L, Sturfelt G, et al. Anti-C1q antibodies in systemic lupus erythematosus. Lupus. 2015;24(1):42\u20139.","journal-title":"Lupus"},{"issue":"Suppl 3","key":"491_CR123","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/ndt\/gfv189.10","volume":"30","author":"L Manenti","year":"2015","unstructured":"Manenti L, Urban ML, Vaglio A, David S. Persistent reduction of serum C3 and lupus nephritis outcome: a retrospective observational study. Nephrol Dial Transpl. 2015;30(Suppl 3):422\u20133.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"491_CR124","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1016\/j.hkjn.2015.08.148","volume":"17","author":"SY Wang","year":"2015","unstructured":"Wang SY, Zhang Y, Xu Y, Chen JH. Persistence of low serum C3 level is associated with higher relapse rate and influences prognosis in lupus nephritis. Hong Kong J Nephrol. 2015;17(2):S56.","journal-title":"Hong Kong J Nephrol"},{"issue":"3","key":"491_CR125","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.amjms.2017.01.005","volume":"353","author":"D Song","year":"2017","unstructured":"Song D, Guo W, Wang F, et al. Complement alternative pathway\u2019s activation in patients with lupus nephritis. Am J Med Sci. 2017;353(3):247\u201357.","journal-title":"Am J Med Sci"},{"issue":"42","key":"491_CR126","doi-asserted-by":"publisher","first-page":"25343","DOI":"10.1074\/jbc.M115.647008","volume":"290","author":"VV Vasilev","year":"2015","unstructured":"Vasilev VV, Noe R, Dragon-Durey MA, et al. Functional characterization of autoantibodies against complement component C3 in patients with lupus nephritis. J Biol Chem. 2015;290(42):25343\u201355.","journal-title":"J Biol Chem"},{"issue":"1","key":"491_CR127","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2215\/CJN.03990415","volume":"11","author":"DJ Birmingham","year":"2016","unstructured":"Birmingham DJ, Bitter JE, Ndukwe EG, et al. Relationship of circulating anti-C3b and anti-C1q IgG to lupus nephritis and its flare. Clin J Am Soc Nephrol. 2016;11(1):47\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"491_CR128","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1681\/ASN.2010060647","volume":"22","author":"L Bao","year":"2011","unstructured":"Bao L, Haas M, Quigg RJ. Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol. 2011;22(2):285\u201395.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"491_CR129","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/ndt\/gfn586","volume":"24","author":"M Chen","year":"2009","unstructured":"Chen M, Xing GQ, Liu FYG, Zhao MH. Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis. Nephrol Dial Transplant. 2009;24(4):1247\u201352.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"491_CR130","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.semnephrol.2013.08.006","volume":"33","author":"JCh Jennette","year":"2013","unstructured":"Jennette JCh, Xiao H, Hu P. Complement in ANCA-associated vasculitis. Semin Nephrol. 2013;33(6):557\u201364.","journal-title":"Semin Nephrol"},{"issue":"1","key":"491_CR131","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00005-013-0254-x","volume":"62","author":"K Ko\u015bcielska-Kasprzak","year":"2014","unstructured":"Ko\u015bcielska-Kasprzak K, Bartoszek D, Myszka M, \u017babi\u0144ska M, Klinger M. The complement cascade and renal disease. Arch Immunol Ther Exp (Warsz). 2014;62(1):47\u201357.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"3","key":"491_CR132","doi-asserted-by":"publisher","first-page":"J276","DOI":"10.1016\/j.jaut.2009.11.014","volume":"34","author":"M Chen","year":"2010","unstructured":"Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun. 2010;34(3):J276\u201386.","journal-title":"J Autoimmun"},{"key":"491_CR133","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.2215\/CJN.00120115","volume":"10","author":"L Manenti","year":"2015","unstructured":"Manenti L, Vaglio A, Gnappi E, et al. Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis. Clin J Am Soc Nephrol. 2015;10:2143\u201351.","journal-title":"Clin J Am Soc Nephrol"},{"key":"491_CR134","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/ki.2012.313","volume":"83","author":"SJ Gou","year":"2013","unstructured":"Gou SJ, Juan J, Chen M, Yu F, Zhao MH. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2013;83:129\u201337.","journal-title":"Kidney Int"},{"key":"491_CR135","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000357154","volume":"126","author":"Y Molad","year":"2014","unstructured":"Molad Y, Tovar A, Ofer-Shiber S. Association of low serum complement C3 with reduced patient and renal survival in anti-myeloperoxidase-associated small-vessel vasculitis. Nephron Clin Pract. 2014;126:67\u201374.","journal-title":"Nephron Clin Pract"},{"issue":"1","key":"491_CR136","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","volume":"170","author":"H Xiao","year":"2007","unstructured":"Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complement pathway in the pathogenesis of disease mediated by anti-neuthrophil cytoplasmic autoantibodies. Am J Pathol. 2007;170(1):52\u201364.","journal-title":"Am J Pathol"},{"issue":"2","key":"491_CR137","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2013020143","volume":"25","author":"H Xiao","year":"2014","unstructured":"Xiao H, Dairaghi DJ. Powers JP el al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014;25(2):225\u201331.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"491_CR138","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrneph.2017.37","volume":"13","author":"M Chen","year":"2017","unstructured":"Chen M, Jayne DRW, Zhao MH. Complement in ANCA associated vasculitis: mechanisms and implications for menagment. Nat Rev Nephrol. 2017;13(6):359\u201367.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"491_CR139","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1365-2249.2012.04615.x","volume":"169","author":"R Kettritz","year":"2012","unstructured":"Kettritz R. How anti-neutrophil cytoplasmic autoantibodies activate neutrophils. Clin Exp Immunol. 2012;169(3):220\u20138.","journal-title":"Clin Exp Immunol"},{"key":"491_CR140","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13075-015-0656-8","volume":"17","author":"SF Chen","year":"2015","unstructured":"Chen SF, Wang FM, Li ZY, Yu F, Zhao MH, Chen M. Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis. Arthritis Res Ther. 2015;17:129.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"491_CR141","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.semnephrol.2013.08.004","volume":"33","author":"H Ma","year":"2013","unstructured":"Ma H, Sandor DG, Beck LH. The role of complement in membranous nephropathy. Semin Nephrol. 2013;33(6):531\u201342.","journal-title":"Semin Nephrol"},{"issue":"1","key":"491_CR142","first-page":"57","volume":"58","author":"T Doi","year":"1984","unstructured":"Doi T, Mayumi M, Kanatsu K, Suehiro F, Hamashima Y. Distribution of IgG subclasses in membranous nephropathy. Clin Exp Immunol. 1984;58(1):57\u201362.","journal-title":"Clin Exp Immunol"},{"key":"491_CR143","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3389\/fimmu.2016.00157","volume":"7","author":"DB Borza","year":"2016","unstructured":"Borza DB. Alternative pathway dysregulation and the conundrum of complement activation by IgG4 immune complexes in membranous nephropathy. Front Immunol. 2016;7:157.","journal-title":"Front Immunol"},{"issue":"6","key":"491_CR144","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00467-009-1439-8","volume":"25","author":"Y Segawa","year":"2010","unstructured":"Segawa Y, Hisano S, Matsushita M, et al. IgG subclasses and complement pathway in segmental and global membranous nephropathy. Pediatr Nephrol. 2010;25(6):1091\u20139.","journal-title":"Pediatr Nephrol"},{"key":"491_CR145","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/ki.1992.143","volume":"41","author":"PE Brenchley","year":"1992","unstructured":"Brenchley PE, Coupes B, Short CD, O\u2019Donoghue DJ, Ballardie FW, Mallick NP. Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy. Kidney Int. 1992;41:933\u20137.","journal-title":"Kidney Int"},{"issue":"4","key":"491_CR146","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/ndt\/gfh008","volume":"19","author":"K Lhotta","year":"2004","unstructured":"Lhotta K, W\u00fcrzner R, Rumpelt HJ, Eder P, Mayer G. Membranous nephropathy in a patient with hereditary complete complement C4 deficiency. Nephrol Dial Transplant. 2004;19(4):990\u20133. https:\/\/doi.org\/10.1093\/ndt\/gfh008 .","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"491_CR147","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00467-014-3004-3","volume":"30","author":"O Niel","year":"2015","unstructured":"Niel O, Dallocchio A, Thouret MC, et al. C3 nephritic factor can be associated with membranous glomerulonephritis. Pediatr Nephrol. 2015;30(2):353\u20135.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"491_CR148","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrneph.2017.156","volume":"14","author":"D Ricklin","year":"2018","unstructured":"Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol. 2018;14(1):26\u201347.","journal-title":"Nat Rev Nephrol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-018-0491-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-018-0491-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-018-0491-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T21:29:49Z","timestamp":1751405389000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-018-0491-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,15]]},"references-count":148,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["491"],"URL":"https:\/\/doi.org\/10.1007\/s10238-018-0491-8","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,15]]},"assertion":[{"value":"21 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}